BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 11220551)

  • 1. Lipid lowering explains the insulin sensitivity enhancing effects of a thiazolidinedione, 5-(4-(2-(2-phenyl-4-oxazolyl)ethoxy)benzyl)-2,4 thiazolidinedione.
    Yakubu-Madus FE; Stephens TW; Johnson WT
    Diabetes Obes Metab; 2000 Jun; 2(3):155-63. PubMed ID: 11220551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability.
    Oakes ND; Thalén PG; Jacinto SM; Ljung B
    Diabetes; 2001 May; 50(5):1158-65. PubMed ID: 11334421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats treated with the thiazolidinedione, MCC-555.
    Upton R; Widdowson PS; Ishii S; Tanaka H; Williams G
    Br J Pharmacol; 1998 Dec; 125(8):1708-14. PubMed ID: 9886762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of CP 68,722, a thiozolidinedione derivative, on insulin sensitivity in lean and obese Zucker rats.
    Bowen L; Stein PP; Stevenson R; Shulman GI
    Metabolism; 1991 Oct; 40(10):1025-30. PubMed ID: 1943727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retinoid X receptor agonists have anti-obesity effects and improve insulin sensitivity in Zucker fa/fa rats.
    Liu YL; Sennitt MV; Hislop DC; Crombie DL; Heyman RA; Cawthorne MA
    Int J Obes Relat Metab Disord; 2000 Aug; 24(8):997-1004. PubMed ID: 10951538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of pioglitazone on hepatic glucose uptake measured with indirect and direct methods in alloxan-induced diabetic dogs.
    Matsuhisa M; Shi ZQ; Wan C; Lekas M; Rodgers CD; Giacca A; Kawamori R; Vranic M
    Diabetes; 1997 Feb; 46(2):224-31. PubMed ID: 9000698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat.
    Oakes ND; Kennedy CJ; Jenkins AB; Laybutt DR; Chisholm DJ; Kraegen EW
    Diabetes; 1994 Oct; 43(10):1203-10. PubMed ID: 7926289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of troglitazone on dexamethasone-induced insulin resistance in rats.
    Okumura S; Takeda N; Takami K; Yoshino K; Hattori J; Nakashima K; Sugimoto M; Ishimori M; Takami R; Yasuda K
    Metabolism; 1998 Mar; 47(3):351-4. PubMed ID: 9500576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prior thiazolidinedione treatment preserves insulin sensitivity in normal rats during acute fatty acid elevation: role of the liver.
    Ye JM; Frangioudakis G; Iglesias MA; Furler SM; Ellis B; Dzamko N; Cooney GJ; Kraegen EW
    Endocrinology; 2002 Dec; 143(12):4527-35. PubMed ID: 12446579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic physiologic hyperinsulinemia impairs suppression of plasma free fatty acids and increases de novo lipogenesis but does not cause dyslipidemia in conscious normal rats.
    Koopmans SJ; Kushwaha RS; DeFronzo RA
    Metabolism; 1999 Mar; 48(3):330-7. PubMed ID: 10094109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals.
    Ikeda H; Taketomi S; Sugiyama Y; Shimura Y; Sohda T; Meguro K; Fujita T
    Arzneimittelforschung; 1990 Feb; 40(2 Pt 1):156-62. PubMed ID: 2334455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of troglitazone on hepatic and peripheral insulin resistance induced by growth hormone excess in rats.
    Sugimoto M; Takeda N; Nakashima K; Okumura S; Takami K; Yoshino K; Hattori J; Ishimori M; Takami R; Sasaki A; Yasuda K
    Metabolism; 1998 Jul; 47(7):783-7. PubMed ID: 9667221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of pioglitazone on glucose metabolism and insulin uptake in the perfused liver and hindquarter of high-fructose-fed rats.
    Ikeda T; Fujiyama K
    Metabolism; 1998 Sep; 47(9):1152-5. PubMed ID: 9751247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of pioglitazone on hepatic and peripheral insulin resistance in Wistar fatty rats.
    Sugiyama Y; Shimura Y; Ikeda H
    Arzneimittelforschung; 1990 Apr; 40(4):436-40. PubMed ID: 2192715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pioglitazone treatment for 7 days failed to correct the defect in glucose transport and glucose transporter translocation in obese Zucker rat (fa/fa) skeletal muscle plasma membranes.
    Hirshman MF; Fagnant PM; Horton ED; King PA; Horton ES
    Biochem Biophys Res Commun; 1995 Mar; 208(2):835-45. PubMed ID: 7695642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects.
    Yu JG; Javorschi S; Hevener AL; Kruszynska YT; Norman RA; Sinha M; Olefsky JM
    Diabetes; 2002 Oct; 51(10):2968-74. PubMed ID: 12351435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pioglitazone-induced increase of insulin sensitivity in the muscles of the obese Zucker fa/fa rat cannot be explained by local adipocyte differentiation.
    Hallakou S; Foufelle F; Doaré L; Kergoat M; Ferré P
    Diabetologia; 1998 Aug; 41(8):963-8. PubMed ID: 9726600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent.
    Fujita T; Sugiyama Y; Taketomi S; Sohda T; Kawamatsu Y; Iwatsuka H; Suzuoki Z
    Diabetes; 1983 Sep; 32(9):804-10. PubMed ID: 6354788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats.
    Fujiwara T; Yoshioka S; Yoshioka T; Ushiyama I; Horikoshi H
    Diabetes; 1988 Nov; 37(11):1549-58. PubMed ID: 3053303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PMT13, a pyrimidone analogue of thiazolidinedione improves insulin resistance-associated disorders in animal models of type 2 diabetes.
    Chakrabarti R; Vikramadithyan RK; Kumar MP; Kumar SK; Mamidi NV; Misra P; Suresh J; Hiriyan J; Rao CS; Rajagopalan R
    Diabetes Obes Metab; 2002 Sep; 4(5):319-28. PubMed ID: 12190995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.